Liviana™ and Medspresso™ announce 4 cocktails for EFC 99

0

Liviana™ and Medspresso™ are pleased to announce the formulation of four cocktails to be served at EFC 99 MMA Fight Night, November 3, 2022 in Johannesburg.

Biomedical Research Institute (OTCBB:MRES)

CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, Oct. 26, 2022 /EINPresswire.com/ — Liviana™ and Medspresso™ announce 4 cocktails for EFC 99

Institute of Biomedical Research (OTC PINK: MRES) (“M2Bio Sciences” or the “Company”), a bioceutical company focused on alternative plant cannabinoids and therapeutic research in mental health, is pleased to share the following update:

Liviana™ and Medspresso™

Liviana™ and Medspresso™ are pleased to announce four revitalizing CBD cocktails to be served at EFC 99 on November 3, 2022 in Johannesburg, South Africa. Extreme Fighting Championship (EFC) is a South African mixed martial arts promotion company established in 2009. It is the largest MMA promotion company on the African continent.

“Our team has worked tirelessly to perfect our unique cocktails. We use premium CBD-infused Medspresso™ and Liviana™ products as key ingredients. EFC 99 guests can stop by the Medspresso™ bar to sample the cocktails, as well as our delicious Liviana™ CBD-infused hummus. Two members of the Cape Town team will join me at EFC 99: Claudia Maschke, sensory therapy manager at M2Bio Sciences and Monique Muller, senior sales and marketing representative at M2Bio Sciences. They will be serving our selection of cocktails and hosting live interviews throughout the evening. – Michael Sachar, CEO of M2Bio Sciences Food and Beverage

Rob Simbowe, Director of Health and Fitness for M2Bio Sciences, will be in action to fight on the main card against Tapiwa Katikati in the lightweight division. The main card begins at 7:00 p.m. and will be shown live on SuperSport Action 210 and SABC Sport Channel. EFC events are currently broadcast in over 120 countries around the world and on numerous television networks in multiple languages.

Guillotine Medspresso™:
This hard-hitting cocktail is made with premium Medspresso™ CBD-infused Tanzanian Peaberry coffee, blended with Kahlúa and Smirnoff vodka.

Liviana™ Concussion:
Perfect for those with a bit of a sweet tooth. It’s made from Liviana™’s CBD-infused wildflower honey, Jack Daniels whiskey, apple juice, sparkling water and a squeeze of fresh lemon.

Medspresso™ Knockout:
Made with premium Medspresso™ Cederberg Rooibos tea, Smirnoff vodka, cranberry juice and fresh mint.

Medspresso™ Back fist without rotation:
This virgin cocktail is made with Medspresso™ Cederberg Rooibos tea, cranberry juice and fresh mint.

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences

Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative medical research into herbal cannabinoids and psilocybin that develops and markets a line of CBD and mushroom products under the Dr. AnnaRx™ brands. , Medspresso™ and Liviana™. Additionally, our research and clinical trials with psilocybin are aimed at new therapies that will help patients with alcohol addiction, mental illness, and cardiovascular disease. Our mission is to advance botanical medicine at the forefront by deploying the best scientific and medical practices, clinical research and emerging technologies. The Company is listed on the NASDAQ OTC bulletin board under the symbol “MRES”.

Publicly listed company (OTC Pink: MRES)

Website: www.m2bio.co
Email: [email protected]

Find Medspresso™ on social networks
Follow us on Facebook: Medspresso
Follow us on Instagram: @medspresso.official
Follow us on LinkedIn: Medspresso™ – More than coffee

Forward-looking statements:
Safe Harbor Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995 The forward-looking statements contained in this press release include the intention, belief or expectations of the company and the members of its management team concerning the future business operations of the company and the assumptions on which these statements are based. Potential investors are cautioned that these forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and that actual results may differ materially from those contemplated by these forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to achieve anticipated sales during negotiation, lack of revenue growth, customer dropouts, failure to achieve improvements performance, efficiency and profitability, and adverse developments in litigation or increases in litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Other factors that could cause actual results to differ materially from those contemplated in this press release can also be found on the Company’s website. The Company assumes no responsibility for updating forward-looking statements.

Jeff Robinson
M2Bio Sciences Food and Beverage (Pty) Ltd
+27 72 333 2148
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

Share.

About Author

Comments are closed.